Schering-Plough's Saphris better than Zyprexa in schizophrenia study
This article was originally published in Scrip
Executive Summary
Schering-Plough's atypical antipsychotic candidate Saphris (asenapine maleate) has met the primary endpoint of a year-long extension study, showing it to be more effective than Lilly's Zyprexa (olanzapine) in reducing the negative symptoms of schizophrenia.